tiprankstipranks
Advertisement
Advertisement

OCUL Stock Latest News

Axpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
RatingsAxpaxli’s Differentiated Long-Acting Profile and Multibillion-Dollar Potential Support Buy Rating and Unchanged $27 Price Target
1d ago
OCUL
Ocular Therapeutix Maintained at Buy as Axpaxli’s Superior Durability Supports Unchanged $18 Price Target
PremiumRatings
Ocular Therapeutix Maintained at Buy as Axpaxli’s Superior Durability Supports Unchanged $18 Price Target
5d ago
OCUL
Clear Street sees less competition for Ocular after EyePoint miss
PremiumThe Fly
Clear Street sees less competition for Ocular after EyePoint miss
5d ago
EYPT
OCUL
Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
PremiumRatings
Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset
5d ago
OCUL
Ocular Therapeutix rises 10.4%
PremiumThe Fly
Ocular Therapeutix rises 10.4%
5d ago
OCUL
Ocular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices
PremiumCompany AnnouncementsOcular Therapeutix Faces Governance and Perception Risks from Insider Equity Compensation and Trading Practices
19d ago
OCUL
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
Premium
Ratings
Ocular Therapeutix Earns Buy Rating on Reduced Regulatory Risk and Strong Axpaxli NDA Visibility
19d ago
OCUL
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)
Premium
The Fly
Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)
19d ago
OCUL
OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
PremiumCompany Announcements
OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market
2M ago
OCUL
Blair adds American Express, Oracle to Conviction List in monthly update
PremiumThe Fly
Blair adds American Express, Oracle to Conviction List in monthly update
2M ago
P
CW
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
PremiumThe Fly
Ocular Therapeutix price target raised to $25 from $21 at H.C. Wainwright
2M ago
OCUL
Ocular Therapeutix price target raised to $30 from $24 at Baird
PremiumThe Fly
Ocular Therapeutix price target raised to $30 from $24 at Baird
2M ago
OCUL
Ocular Therapeutix trading resumes
PremiumThe FlyOcular Therapeutix trading resumes
2M ago
OCUL
Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
Premium
The Fly
Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA
2M ago
OCUL
Ocular Therapeutix to resume trading at 9:15 am ET
Premium
The Fly
Ocular Therapeutix to resume trading at 9:15 am ET
2M ago
OCUL
Ocular Therapeutix trading halted, news pending
PremiumThe Fly
Ocular Therapeutix trading halted, news pending
2M ago
OCUL
Ocular Therapeutix Expands Equity Plan and Confirms Leadership
PremiumCompany Announcements
Ocular Therapeutix Expands Equity Plan and Confirms Leadership
2M ago
8K
OCUL
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
PremiumCompany Announcements
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
4M ago
OCUL
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
PremiumRatings
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18
4M ago
OCUL
Axpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
PremiumRatingsAxpaxli’s Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
4M ago
OCUL
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
Premium
Ratings
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
4M ago
OCUL
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)
Premium
The Fly
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)
4M ago
OCUL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >